trial

Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building

NCTId NCT04446234
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 350 (estimated)
Sponsored by Shanghai Mental Health Center
Primary completion 2022-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
350 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2021-05
Primary completion
2022-12-31
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
RisperidoneAripiprazoleZiprasidoneAmisulprideQuetiapine

Sponsors

Shanghai Mental Health CenterLead Sponsor
Shanghai Jiao Tong University School of MedicineCollaborator

Investigators

1
LV QINYUPrincipal Investigator

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
350
Phase
PHASE4
Primary Completion Date
2022-12-31
Status
UNKNOWN
relationships
The graph out of here
drug
Risperidone
drug
Aripiprazole
drug
Ziprasidone
drug
Amisulpride
drug
Quetiapine
drug
lead_sponsor
Shanghai Mental Health Center
company
collaborator
Shanghai Jiao Tong University School of Medicine
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
LV QINYU
person